Graviton Bioscience Corp. is a clinical-stage drug discovery and development firm dedicated to developing innovative therapies for patients with fibrotic, autoimmune, and CNS diseases. Their scientific team focuses on alleviating disease and restoring homeostasis through multiple molecular pathways.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/01/2024 | Series B-1 | $25MM | $xx.xx | $252.08MM | Sanofi | |
Price per Share
$xx.xx
Shares Outstanding
4,063,223
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Sanofi
|
||||||
01/02/2024 | Series A-1C | $25MM | $xx.xx | $202.75MM | Enavate Sciences | |
Price per Share
$xx.xx
Shares Outstanding
5,747,126
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Enavate Sciences
|
||||||
12/20/2022 | Series A-1A | $29.82MM | $xx.xx | $167.66MM | Pontifax | |
Price per Share
$xx.xx
Shares Outstanding
9,466,507
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Pontifax
|
||||||
12/20/2022 | Series A-1B | $10MM | $xx.xx | $167.66MM | Pontifax | |
Price per Share
$xx.xx
Shares Outstanding
2,564,102
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Pontifax
|
||||||
02/04/2021 | Series A | $3.5MM | $xx.xx | $23.33MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
866,336
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|